The long-term objective of this research project is to obtain a better understanding of the molecular mechanisms governing the first step in tumor cell dissemination, namely motility. To accomplish this goal it is proposed to define the biological function and mechanism of action of an autocrine motility factor (AMF) and its receptor (gp78). AMF was originally identified in 1986, as a proteinaceous molecule that stimulated the locomotion of self-producing cells, hence its name. Until recently, its molecular identity had proved extremely elusive. We have found during this granting period (1996, partial protein sequencing, 1998 molecular cloning), that AMF was previously identified as three different proteins, i.e., neuroleukin (NLK), phosphohexose isomerase (PHI) and a maturation factor (MF), and each was independently implicated in cell motility and mitogenicity. AMF/NLK/PHI/MF exerts its signal through ligation to a cell surface receptor (gp78) whose predicted secondary structure displays seven putative helical transmembrane domains, a structural feature shared by all members of the G-protein-coupled receptor class of transmembrane proteins. We have shown that the expression levels of both receptor and ligand determine cell motility in vitro and serve as prognostic markers for tumor progression in vivo. On the basis of these observations, we set the following four specific aims in this renewal application:
Specific Aim 1) To study the regulation of AMF gene expression in normal and high- and low-metastatic cancer cells;
Specific Aim 2) To study the structural-functional relationship of AMF activity;
Specific Aim 3) To establish the secretory pathway of AMF;
Specific Aim 4) To study the consequences of AMF/receptor-binding leading to differential morphological changes, membrane ruffling and cell motility in high- and low-metastasizing cancer cells. It is expected that the accomplishment of these aims will help in obtaining our goal of unveiling how the autocrine loop of AMF signaling through its receptor alters cellular properties, and how it can be exploited for therapeutic interventions of invading cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA051714-11
Application #
6172120
Study Section
Special Emphasis Panel (ZRG1-MEP (01))
Program Officer
Ault, Grace S
Project Start
1991-08-01
Project End
2003-05-31
Budget Start
2000-07-28
Budget End
2001-05-31
Support Year
11
Fiscal Year
2000
Total Cost
$284,735
Indirect Cost
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Wang, Ying; Ha, Seung-Wook; Zhang, Tianpeng et al. (2014) Polyubiquitylation of AMF requires cooperation between the gp78 and TRIM25 ubiquitin ligases. Oncotarget 5:2044-51
Kho, Dhong Hyo; Zhang, Tianpeng; Balan, Vitaly et al. (2014) Autocrine motility factor modulates EGF-mediated invasion signaling. Cancer Res 74:2229-37
Kho, Dhong Hyo; Nangia-Makker, Pratima; Balan, Vitaly et al. (2013) Autocrine motility factor promotes HER2 cleavage and signaling in breast cancer cells. Cancer Res 73:1411-9
Ahmad, Aamir; Ali, Shadan; Ahmed, Alia et al. (2013) 3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells. PLoS One 8:e54657
Yanagawa, Takashi; Shinozaki, Tetsuya; Watanabe, Hideomi et al. (2012) Vascular endothelial growth factor-D is a key molecule that enhances lymphatic metastasis of soft tissue sarcomas. Exp Cell Res 318:800-8
Ahmad, Aamir; Aboukameel, Amro; Kong, Dejuan et al. (2011) Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 71:3400-9
Niinaka, Yasufumi; Harada, Kiyoshi; Fujimuro, Masahiro et al. (2010) Silencing of autocrine motility factor induces mesenchymal-to-epithelial transition and suppression of osteosarcoma pulmonary metastasis. Cancer Res 70:9483-93
Araki, Kenichiro; Shimura, Tatsuo; Yajima, Toshiki et al. (2009) Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem 284:32305-11
Funasaka, Tatsuyoshi; Hogan, Victor; Raz, Avraham (2009) Phosphoglucose isomerase/autocrine motility factor mediates epithelial and mesenchymal phenotype conversions in breast cancer. Cancer Res 69:5349-56
Funasaka, Tatsuyoshi; Hu, Huankai; Hogan, Victor et al. (2007) Down-regulation of phosphoglucose isomerase/autocrine motility factor expression sensitizes human fibrosarcoma cells to oxidative stress leading to cellular senescence. J Biol Chem 282:36362-9

Showing the most recent 10 out of 59 publications